Skip to content
Mitsui Invests in E12 Ventures, a US-based Venture Capital Fund

Mitsui Invests in E12 Ventures, a US-based Venture Capital Fund

Mitsui & Co., Ltd. (“Mitsui”, Head Office: Tokyo, President and CEO: Kenichi Hori), together with The Norinchukin Bank (President and CEO: Kazuto Oku), Mitsubishi Pencil Company, Limited (President: Shigehiko Suhara), and Nitto Denko Corporation (President: Hideo Takasaki) (hereinafter collectively “the Limited Partners”), announced its capital commitment to E12 Venture Capital Fund I, L.P. (“E12 Fund I”) upon its final closing.

Two people shaking hands

Beigene and Ensem Therapeutics Announce Partnership to Advance Differentiated CDK2 Inhibitor

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, and Ensem Therapeutics, Inc. (ENSEM), a biotechnology company focusing on high-value and difficult-to-drug oncology targets, today announced an agreement for BeiGene to acquire an exclusive global license to an Investigational New Drug (IND) application-ready oral cyclin-dependent kinase 2 (CDK2) inhibitor.

Happy Doctor Evaluating Patient

QurAlis Receives Clinical Trial Authorisation (CTA) in the U.K. for QRL-201, a First-in-Class STATHMIN-2 Precision Therapy for ALS

QurAlis Corporation, a clinical-stage biotechnology company developing breakthrough precision medicines for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases with genetically validated targets, today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom (U.K.) has completed review of the Clinical Trial Application (CTA) and has issued a notice of acceptance for QRL-201 for the potential treatment of ALS.

Back To Top